相关实验视频
Updated: Jan 14, 2026

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
23.0K
帕金森病患者的深度大脑刺激的长期运动和认知结果 患有GBA1致病变体的帕金森病患者
Micol Avenali1,2, Carlo Alberto Artusi3,4, Roberto Cilia4
1Department of Brain and Behavioural Sciences, University of Pavia, Italy.
Neurology
|October 22, 2025
概括
深度大脑刺激 (DBS) 对患有GBA1变异 (GBA-PD) 的帕金森病 (PD) 患者提供了运动益处. 在GBA-PD的认知衰退与GBA1基因型有关,而不是DBS治疗本身.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 神经学 神经学
背景情况:
- 深度大脑刺激 (DBS) 是帕金森病 (PD) 的标准治疗方法.
- 有关GBA1变异携带者 (GBA-PD) 治疗DBS的潜在认知衰退加速存在担忧.
- 本研究研究了GBA1基因型和DBS对长期PD结果的综合影响.
研究的目的:
- 为了评估经过DBS的GBA-PD患者的长期运动和非运动结果.
- 为了比较DBS治疗的GBA-PD患者,未治疗的GBA-PD患者和DBS治疗的非GBA-PD患者之间的结果.
- 评估GBA1变异类和DBS目标对临床结果的影响.
主要方法:
- 一项多中心,回顾性,受控的意大利研究包括615名参与者,分为三个组:DBS治疗的非GBA-PD,DBS治疗的GBA-PD和非手术的GBA-PD.
- 临床评估 (认知,运动,非运动) 在基线和干预后长达5年的时间进行.
- 统计分析包括千二测试,克鲁斯卡尔-瓦利斯测试和线性混合效应模型的纵向变化.
主要成果:
- 两个DBS组都表现出显著的运动改善,与未经操作的GBA-PD组不同.
- 在5年内,GBA-PD组 (DBS和非DBS) 的痴呆发病率高于DBS-非GBA-PD组.
- 幻觉和尿路问题在GBA-PD组中增加,而不管DBS治疗.
结论:
- DBS是一种可行的治疗GBA-PD,提供持续的运动症状缓解和改善生活质量.
- 在GBA-PD中观察到的加速认知衰退是由于GBA1基因型而不是DBS程序.
- 进一步的研究可能会探索特定的GBA1变异效应和最佳的DBS目标.
更多相关视频
相关概念视频
Parkinson's Disease: Treatment
972
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
972
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

